FOLLICULAR LYMPHOMA

This study compares standard radiation (24 Gy) to a very low dose (4 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well but causes fewer side effects. About 375 participants will be enrolled, and the study is currently …

This study tests a new vaccine (EO2463) for people with slow-growing non-Hodgkin's lymphoma. The vaccine is designed to help the immune system attack cancer cells. It is given alone or with standard drugs. About 80 adults with follicular or marginal zone lymphoma will take part. …

This study is testing an experimental drug called LY4584180 in adults with certain blood cancers (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors.…

This study is for people with early-stage follicular lymphoma, a slow-growing blood cancer. It compares standard radiation therapy alone to radiation plus a drug called obinutuzumab. The goal is to see if adding the drug helps keep the cancer from coming back longer. About 190 pa…

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This study tests whether combining two drugs, epcoritamab and rituximab, can effectively treat follicular lymphoma in people who haven't had treatment before. About 100 adults with this slow-growing blood cancer will receive the drug combination. The goal is to see if the cancer …

This early-phase study is testing a new treatment for adults with certain types of blood cancer (B-cell lymphomas) that have returned or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR…

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study tests whether a combination of two drugs, loncastuximab tesirine and rituximab, can make follicular lymphoma disappear completely in people whose cancer has returned or not responded to prior therapy. About 100 adults with this type of lymphoma will receive the treatme…

This study tests a combination of a CAR T-cell therapy (axicabtagene ciloleucel) and radiation in 20 adults with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if the combination is safe and helps control the disease. P…

This study tests a two-drug combination (orelabrutinib and rituximab) followed by a maintenance drug (orelabrutinib) in people whose follicular lymphoma has come back or not responded to prior treatment. The goal is to see if this approach can shrink tumors and keep them from gro…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib. Researchers want to see how the drug affects quality of life and how often patients need hospital care. Th…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to seek out and destroy cancer cells while sparing healthy ones. The study aims to fin…

This early-stage study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals…

This study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests whether combining two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take the drugs and be monitored for tumor response and side effects. The goal is to contr…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests whether a new drug called golcadomide combined with rituximab works better than standard treatments for people with follicular lymphoma that has returned or stopped responding to prior therapy. About 400 adults will be randomly assigned to either the new combo or…

This study tests whether the drug mosunetuzumab, given alone or with zanubrutinib, can shrink or eliminate tumors in people recently diagnosed with follicular lymphoma who have not yet had treatment. About 152 adults with advanced or bulky disease will receive the drugs and be mo…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a type of blood cancer. The goal is to see how well the treatment shrinks or controls the cancer. About 34 adults with stage II bulky or stag…

This study tests whether the drug epcoritamab can help people with follicular lymphoma whose cancer did not completely go away after standard first treatment. About 35 adults with advanced-stage disease will receive epcoritamab as a second-line therapy. The main goal is to see ho…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants receive the drugs in cycles, with adjustments based on how well the cancer responds. The goal is to see how many peop…

This study gives patients with large B-cell lymphoma or follicular lymphoma access to a CAR T-cell therapy called axicabtagene ciloleucel, even when their specific batch didn't meet commercial quality standards. The treatment is still considered safe and effective enough for use …

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study tests a combination of two drugs, mosunetuzumab and zanubrutinib, in people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if the combo can shrink tumors and improve response rates. About 56 adults will receive the t…

This study follows about 700 adults with advanced diffuse large B-cell lymphoma or follicular lymphoma who are receiving epcoritamab as part of their routine care. Researchers will track how well the drug works in real-world settings over up to 3 years. The goal is to see how man…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This study tests a drug called odronextamab in 35 adults with untreated, low-tumor follicular lymphoma. The goal is to see if the drug can shrink or eliminate tumors. Participants receive the drug as an infusion, and researchers will monitor how well it works and any side effects…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study tests a new type of PET scan that targets a protein called CD70, which is found on some cancer cells. The goal is to see if this scan can better detect kidney cancer, lymphoma, and nasopharyngeal cancer compared to standard scans. About 300 adults with known or suspect…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study is analyzing stored blood and tissue samples from 654 people with advanced follicular lymphoma to learn more about genetic changes linked to the disease. The goal is to find better ways to predict how the cancer will behave and respond to treatment. Participants are no…

This study looks at how the flu and COVID vaccines affect the immune system in people with different types of lymphoma. Researchers will measure antibody levels and immune cells over time, comparing them to people without lymphoma. The goal is to better understand how lymphoma an…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…

This study aims to collect blood, tissue, and other samples from 200 adults with untreated follicular lymphoma. Researchers will track participants for up to 5 years to see how the cancer evolves and responds to therapy. The goal is to better understand the disease to design futu…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…